Posted on 08/03/2010 in Pharmaceutical Company Product News Pfizer's pain relief treatment pregablin has demonstrated its efficacy in a new clinical study conducted in Europe.
Results from the trial published in the European Journal of Neurology showed that pregablin, which is marketed by Pfizer under the name Lyrica, can be effective as a means of treating neuropathic pain resulting from traumatic injury.
This conclusion was reached following a placebo-controlled study conducted among patients suffering from such ailments for more than four years, with the drug also helping to reduce associated problems such as sleep disturbance.
Dr Michael Serpell, senior clinical lecturer in anaesthetics for the university section of anaesthesia, pain and critical care medicine at Gartnavel General Hospital in Glasgow, said the results should "provide hope" for chronic pain sufferers.
He added: "This study is also encouraging for clinicians who traditionally find neuropathic pain resulting from trauma a challenging condition to treat effectively."
Last week, the efficacy of Pfizer's rheumatoid arthritis drug Enbrel was underlined by results from a clinical trial which showed that a majority of patients achieved remission when treated with the medication.Other news stories from 08/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
